At odNOVA, a treatment appointment is a structured clinical process. I allocate a 55 min for each visit so that precision, safety, and patient comfort are never compromised by a rushed schedule.

There is time throughout the session for questions and discussion.

Nothing is done under pressure, and nothing moves forward simply because you arrived intending to have treatment.

You are always free to pause, reconsider, or decide not to proceed.

There is nothing wrong with leaving without treatment if that is the right decision for you on the day.

​

1. Assessment before treatment

Your appointment begins with a clinical assessment, not with injections. I evaluate your anatomy, muscle movement, and the areas of concern to decide what is realistically achievable. My role is to offer honest clinical judgement, not automatic agreement. If I believe a treatment will add little value or is not in your best interests, I will say so clearly.

2. Baseline documentation

Clinical photography is a standard part of my practice. With your consent, high-resolution photographs are taken to support accurate treatment planning, objective review, and clear documentation of your progress over time. This ensures transparency and clinical accountability from day one.

3. Preparation before the appointment

Before your visit, you will receive medical history and consent forms through a secure portal. Completing these in advance is an important part of the process, as it allows us to use the appointment for discussion, preparation, and treatment rather than paperwork. If anything remains unclear, we will go through it together during the session.

4. Risk discussion and informed consent

We discuss potential side effects and realistic expectations in direct, transparent terms.

This includes both common transient effects and the rarer complications you should still understand before proceeding.

Treatment only goes ahead once I am satisfied that it is clinically appropriate, and once you feel fully informed, comfortable, and ready. This is a collaborative process, and both of us should feel comfortable with the decision.

5. The treatment itself

The injections themselves are precise and usually very quick. A topical numbing cream is applied beforehand, and I use extra-fine needles and to keep the procedure as controlled and comfortable as possible.

6. The environment

A clinical procedure does not need to feel tense. I aim to create a space that feels calm, settled, and unhurried — piano music in the background and, if time allows, a cup of tea. These are not mere details; they are part of a standard of care that values the patient experience as much as the clinical outcome.

A note on trust

Many of my patients have stayed with me for years, and I value that deeply.

But I do not expect trust to be automatic. Trust has to be built through consistency, transparency, and results.

My role is to give you the information, the assessment, and the space to make the right decision for yourself.

You will receive full written aftercare by email after your appointment, but the main priorities are straightforward.

​

For the rest of the day, keep the treated area relatively undisturbed.

Avoid rubbing or massaging it, and leave make-up off until later in the day or, ideally, until the following morning.

 

Intense exercise is best postponed for 24 hours, and I generally advise keeping the rest of the day calm rather than unnecessarily active.

​

Some traditional aftercare rules in aesthetic practice are precautionary rather than strongly evidence-based.

Current literature suggests that stricter rules such as remaining upright for several hours are not supported by strong published evidence in all patients, and a 2025 study of 5014 upper-face treatments found no increase in complications when post-treatment precautions were limited to the first 10 minutes.

 

Even so, I still advise patients to treat the area gently and avoid unnecessary irritation immediately after treatment, because good aftercare is ultimately about protecting a well-planned result. 

​

Minor local effects such as redness, slight swelling, tenderness, bruising, or headache can occur in the first few days and are usually temporary.

UK prescribing information states that adverse reactions generally occur within the first few daysafter injection and are usually transient. 

​

Review matters

The result should not be judged too early. Treatment continues to settle over the first 2 weeks, which is why review remains an important part of the process. At odNOVA, the clinical review helps me assess the settled result properly, discuss your response with you, and use that information to plan future treatment with greater precision.

In most cases, discomfort is minimal.

The injections are brief and are usually felt as a small sharp pinch or a short-lived stinging sensation rather than significant pain.

​

Beyond the Needle

How comfortable treatment feels depends on more than individual sensitivity alone. It is also shaped by preparation, technique, and the way the appointment is conducted. These details matter more than many patients realise.

In some settings, appointments are kept very short and numbing cream is not routinely used. That is not how I work.

​

The odNOVA Protocol

At odNOVA, patient comfort is an integrated part of the clinical standard.

A numbing cream is applied before treatment to reduce sensation and make the procedure easier to tolerate.

Appointments are never rushed. Each session is given the time it needs so that the experience feels controlled, calm, and properly managed from start to finish.

​

The aim is not simply to inject quickly, but to ensure that each placement is carried out with professional rigour and anatomical focus.

At odNOVA, anti-wrinkle treatment is approached as a complete clinical pathway rather than a single appointment.

​

I do not treat the second visit as a routine “top-up”. It is a Clinical Review, carried out once the full biological effect has had time to declare itself properly.

That is why the review takes place after the 14-day mark, when the true outcome of treatment can be assessed with accuracy.

​

This review is important because it allows me to evaluate the result of the first treatment properly: how the muscles have responded, how the balance between muscle groups has settled, and whether the original dosing and placement achieved the intended effect.

 

In some patients, no further adjustment is needed. In others, a small refinement may be appropriate. In some cases, the difference between the initial plan and the final requirement can be more substantial. That is precisely why review matters.

​

The purpose of review is not simply to “add more”. It is to understand your individual response and use that information intelligently.

 

The total number of units used at the first treatment, together with any refinement carried out at review, becomes the most useful reference point for planning your next appointment. That means the second treatment is not planned in isolation; it is based on observed response, not guesswork.

​

The same principle applies over time. At each stage, your feedback matters. The better I understand how you experienced the result — whether positive or negative — the more precisely I can shape the next treatment around your anatomy, movement, and preferences.

 

This is how treatment becomes more accurate, more consistent, and more individual over time.

​

After several treatment cycles, the process usually becomes far more predictable, because we have already established the dose and placement pattern that gives you the result you prefer. At that point, formal review may become less necessary in practical terms.

Even so, Clinical Review remains available to all odNOVA patients and is included in the treatment fee whenever it is wanted or clinically useful.

​

At odNOVA, you are paying for a properly managed clinical outcome, not simply for treatment on the day. My fee reflects the full professional process: consultation, treatment, and review.

Not immediately. The effect develops gradually over the first several days as muscle activity begins to soften.

​

The Clinical Timeline
Most patients start to notice a change between days 3 and 7, but the final result is only judged at around 2 weeks.

It is important to understand that early movement is normal; it does not mean the treatment is weak or ineffective. It simply means the biological response is still developing.

​

Why I Wait Until Day 14
I do not assess the result prematurely. A proper clinical review must be based on the settled effect, once the balance between muscle groups has fully stabilised.

 

True anatomical assessment can only happen at the 14-day mark, when the treatment has declared itself properly.

​

At odNOVA, the 2-week review is included as part of treatment, because I do not regard anti-wrinkle treatment as complete on the day of injection alone.

When treatment is assessed, prescribed, and delivered properly, complications and sub-optimal results are uncommon.

 

When outcomes are poor, the problem is usually not the concept of treatment itself, but the way the clinical pathway was handled—specifically in assessment, planning, dosing, technique, or patient selection.

​

Technical and Strategic Failures
Issues such as heaviness, unnatural brow positioning, or eyelid drooping are usually treatment-related complications rather than unpredictable events. They are most often associated with poor injection technique, an inadequate appreciation of muscle balance, or the use of a fixed template instead of an individual anatomical assessment.

Precision in placement and depth is what distinguishes a professional clinical outcome from a complication.

​

Product Handling and Clinical Judgement
Results may also be sub-optimal when treatment is under-dosed, poorly planned, or prepared inconsistently. In these cases, the failure is usually one of clinical judgement and execution.

Issues such as poor reconstitution can affect delivered concentration and diffusion characteristics, leading to results that are either unpredictable or fade prematurely.

​

Governance and Sourcing
Patient safety depends on proper prescribing oversight, regulated sourcing, and clear clinical accountability. The use of unlicensed or grey-market products, often handled outside of strict pharmaceutical cold-chains, remains a primary risk factor. Weak governance is one of the clearest markers of poor practice.

​

Patient Selection
Treatment is also more likely to fail when the wrong patient is treated, or when a pre-existing feature has not been recognised during the consultation.

Pre-existing eyelid heaviness, marked structural asymmetry, or certain neuromuscular conditions all change what is clinically appropriate. 

Professional practice often involves knowing when the correct clinical decision is not to treat.

​

My Approach
Every treatment begins with a face-to-face consultation, a detailed anatomical assessment, and a prescribing decision based on your movement pattern, baseline structure, and goals.

​

The objective is not simply to inject, but to treat precisely, safely, and with respect for natural expression.

The effect is not abrupt. It fades gradually as neuromuscular transmission recovers and the treated muscle slowly regains contractile activity.

 

In most cases, the clinical effect persists for 3 to 4 months, though exact longevity is an individual variable determined by muscle mass, movement patterns, treatment area, dose, and metabolic response.

​

How does movement return?

Recovery is a biological process, not a mechanical wearing off. Movement typically returns first in the strongest and most active muscle groups—most commonly the glabellar (frown) complex. While more delicate areas may remain quieter for longer, the recovery of function is gradual.

This process is associated with "synaptic sprouting" — the formation of new nerve terminals that re-establish muscle communication over time.

​

Does repeat treatment make results last longer?

Often, yes. This is not because the product “builds up”, but because a repeatedly relaxed muscle may become less forceful over time. With appropriately timed interventions, the muscle is used less aggressively, which can reduce its bulk and contractile dominance.

In practice, this leads to more stable results, softer line formation, and occasionally longer intervals between sessions.

​

What happens as the effect fades?

The muscle simply returns to its baseline level of activity. There is no rebound phenomenon, and treatment does not make lines worse than baseline.

What happens is more straightforward: as movement returns, the skin resumes its natural folding pattern, and lines gradually re-emerge in keeping with your underlying anatomy and expression.

​

Why does timing matter?

This is where poor practice shows. Repeat treatment should not be approached mechanically. 

My approach is to assess muscle recovery, movement patterns, and anatomical balance before deciding whether repeat treatment is actually appropriate.

 

A minimum interval of 12 weeks matters, but high-standard practice depends on individual assessment, not routine recall alone.

When a result is weak or short-lived, the issue is rarely the medicine itself. More often, it is a failure of clinical strategy — specifically dose selection, treatment planning, or anatomical precision.

​

Sub-therapeutic dosing

One of the commonest reasons for a poor result is that the dose was simply too low for the strength and behaviour of the muscle being treated. Stronger, more active muscle groups require enough units, placed in the right pattern, to achieve a meaningful effect.

When treatment is approached too conservatively, the result may fade prematurely — not because treatment has “stopped working”, but because the dose was insufficient from the outset.

​

Long-term responsiveness

In some cases, reduced responsiveness over time can become part of the picture. Official prescribing information is clear that injections given too frequently may increase the risk of neutralising antibody formation, which can reduce the effectiveness of future treatment.

​

Anatomical precision

Dose alone does not determine success. Outcome also depends on how accurately treatment is placed in relation to muscle depth, movement pattern, and the mechanics of facial expression. A few millimetres can change the result significantly. Facial anatomy is never generic, and treatment should not be either.

​

My approach

At odNOVA, treatment is planned through anatomical assessment, dose selection, and precise placement.

The aim is not simply to inject, but to understand why a previous result may have been weaker than expected — and how to approach it more intelligently next time.

In the UK, botulinum toxin (Botox) is a Prescription-Only Medicine (POM).

 

In cosmetic practice, treatment should begin with a proper face-to-face clinical assessment and a prescribing decision made by an appropriately qualified prescriber.

​

Professional guidance is also clear that remote prescribing for cosmetic procedures is not acceptable, and in England cosmetic botulinum toxin treatment is illegal for anyone under 18. 

​

The reality of UK practice

The person prescribing and the person injecting are not always the same. That is precisely where standards begin to separate.

​

Prescribing is the medical decision. Injecting is the technical act of treatment.

Safe care depends on those two parts remaining under proper clinical governance. Where treatment is delegated, the prescriber still retains clinical responsibility for the prescribing decision and for ensuring that the person administering treatment is competent to do so safely. 

​

Why this matters

When care is fragmented, accountability becomes weaker. The clinician who assessed your anatomy, medical history, and suitability may not be the person carrying out the treatment itself. That is not how I practise.

​

The odNOVA standard: continuity of care

At odNOVA, your treatment pathway is not split between different people at different stages. You are seen face to face by me, assessed by me, prescribed by me, and treated by me.

​

As a Pharmacist Independent Prescriber with a Master’s degree in Cosmetic and Aesthetic Medicine and ongoing postgraduate study in Dermatology, I take clinical responsibility for your treatment from the initial consultation to the final result.

 

That continuity matters. It means consistency, accountability, and a treatment plan shaped by the same clinician throughout — not handed from one pair of hands to another.

There is no universal “best” product in the abstract, because licensed botulinum toxin brands are not identical medicines.

​

Different formulations have different pharmaceutical characteristics, and they should not be treated as interchangeable.

Even their unit systems are product-specific, which is why dosing between brands cannot be translated casually from one to another. 

​

In practice, that matters. Different brands may be chosen for different reasons depending on the treatment area, the strength and behaviour of the muscle, previous response, and the level of precision or spread required in the treatment plan.

​

My academic work included close study of different botulinum toxin formulations, which is one of the reasons I do not treat product selection as superficial.

 

The medicine matters, but so does the anatomy, the dosing strategy, the placement, and the judgement behind the plan.

So the real question is not simply which brand is “best”. The better question is which formulation is most appropriate for your face, your movement pattern, and the clinical objective we are trying to achieve.

​

At odNOVA, I use only UK-licensed, pharmacy-sourced medicines.

During consultation, I explain not only what I recommend, but why that particular choice makes the most clinical sense for you.

Most patients can be treated safely, but there are situations where treatment is not appropriate, or where it needs a much more careful medical assessment first.

​

I would not proceed with treatment if you are: pregnant or breastfeeding, if you have an active infection in the area being treated, or if you have a known allergy to the medicine or any of its ingredients.

 

Treatment may also be unsuitable in patients with certain neuromuscular conditions, including disorders such as Myasthenia Gravis, Lambert–Eaton syndrome, or motor neurone disease, because these can increase the risk of excessive muscle weakness. 

​

There are also situations where treatment is not automatically ruled out, but where I assess things more carefully.

These include bleeding disorders, anticoagulant therapy, swallowing difficulties, significant weakness or atrophy in the muscles being considered for treatment.

​

Medication matters as well.

Certain drugs, including aminoglycoside antibiotics and some muscle relaxants, can affect neuromuscular transmission and may increase the effect of treatment in a way that requires extra caution. 

​

This is why I do not treat suitability as a box-ticking exercise.

Every prescription is preceded by a full consultation with me.

If treatment is not clinically appropriate, I will explain why clearly and discuss safer or more suitable alternatives where relevant.

When properly prescribed and administered, botulinum toxin has a long-established medical safety record.

​

Most patients experience little to no downtime.

Minor, short-lived effects can include localised redness, slight swelling, bruising, a temporary headache, or a feeling of heaviness as the muscles adjust. These are recognised responses and usually settle without intervention.

​

Where the real risk lies

The greatest risks in this field are rarely about the medicine in isolation. They are usually about clinical standards.

Risk rises when treatment is carried out without a proper face-to-face clinical assessment, when the injector lacks a sound understanding of functional facial anatomy, when aseptic technique and clinical protocols are poor, or when products are sourced outside regulated pharmaceutical channels.

​

Undesirable effects are also more likely where injections are misplaced, where there is unrecognised pre-existing muscle weakness, or where the patient’s medical history and medication profile have not been assessed properly.

​

The odNOVA standard

Safe treatment depends not only on what is used, but on the judgement, anatomical understanding, and clinical governance behind it.

 

I do not treat this as a casual cosmetic procedure. It is a clinical intervention that requires accountability from the initial assessment to the final result.

A cooling-off period is time set aside between consultation and treatment so that any decision to proceed is made with clarity, proper understanding, and no sense of pressure.

​

At odNOVA, first consultation and treatment are not treated as the same event. If you are attending for a first consultation, or discussing a new treatment area for the first time, treatment is not carried out there and then. That pause is deliberate.

​

Its purpose is simple: to give you time to reflect on what we discussed, consider the proposed treatment properly, and decide without being carried along by the momentum of the appointment itself.

​

Informed consent depends on more than information alone. It also depends on time.

 

GMC and GPHC guidance is clear that patients need time to reflect before making a decision about a cosmetic procedure, and JCCP also advises allowing a cooling-off period before proceeding. 

​

My role is not simply to make treatment available on demand. It is to make sure that, if you go ahead, you do so with a clear head, a proper understanding of the plan, and genuine confidence in the decision.

Even when treatment is otherwise suitable, there are times when delaying it is simply the better clinical decision.

​

I may advise postponing treatment if you are: currently unwell, if you have an active facial or sinus infection, if you have recently had or are about to have dental treatment, if you have recently had a vaccination or another medical procedure, or if you have an important professional or social event in the next 7 to 10 days where even minor bruising or swelling would be unwelcome.

​

This does not always mean treatment is formally unsuitable.

 

In many cases, it is simply a matter of timing, judgement, and reducing unnecessary variables around the appointment.

​

Where there is active infection or inflammation in the area being treated, the issue becomes more than a matter of convenience and may be a genuine reason not to proceed.

 

Equally, a careful review of your medical history, current health, and timing around other procedures helps me decide whether treatment should go ahead now or be deferred until conditions are more appropriate.

​

My role is not simply to treat at the earliest opportunity, but to make sure treatment is carried out under the right conditions, for the right reasons, and at the right time.

Botulinum toxin (Botox) is most often associated with facial aesthetics, but that is only part of the picture. It also has an established place in wider medical practice, which is one of the reasons I think it should always be approached with respect.

​

In aesthetic practice, treatment is used to soften movement-related lines and to reduce patterns of muscular tension that can affect facial balance, expression, or lower-face strain.

​

Common treatment areas include:

• the frown area

• the forehead

• crow’s feet

• bunny lines

• the eyebrows

• gummy smile

• lip flip

• downturned mouth corners

• the chin

• the masseters (grinding)

• platysma / neck bands (neck)

​

In some cases, treatment may also be used more selectively to improve facial symmetry, refine movement, or support a more rested appearance.

​

Medical and functional use

Outside aesthetics, the same treatment may also be used in selected medical settings.

 

These include chronic migraine and excessive sweating (hyperhidrosis), as well as certain other functional or neurological indications where appropriate assessment and prescribing are required.

​

Why this matters

That broader medical background matters because it places aesthetic treatment in the right context.

This is not something I see as a casual cosmetic purchase or a menu of areas. It is a prescription treatment, and suitability should always be based on anatomy, medical history, movement pattern, and treatment objective.

​

My approach

My role is not simply to inject.

It is to assess whether treatment is appropriate, explain where it may help, and carry it out carefully, precisely, and with respect for natural expression.

Botulinum toxin type A is an approved preventive treatment for adults with chronic migraine.

 

In UK practice, this means a headache pattern of 15 or more headache days per month, with at least 8 having migraine features, and it is generally considered only after at least 3 prior preventive treatments have not worked adequately and medication overuse has been addressed. 

​

The neurological rationale

Its role in migraine is not simply muscular. The clinical objective is neuromodulation: reducing the release of pain-related neurotransmitters and dampening peripheral input into the central nervous system, which is thought to reduce central sensitisation in chronic migraine. 

​

Clinical protocol vs aesthetic treatment

This is a medical protocol, not a cosmetic one. The licensed PREEMPT-style regimen uses a baseline dose of 155 units delivered across 31 injection sites, with the option to increase to 195 units across up to 39 sites depending on the pain distribution and clinical response.

 

Injection sites span the forehead, temples, occipital region, cervical paraspinal area, and trapezius, which is entirely different from routine aesthetic upper-face work. 

​

Response and maintenance

Improvement is not judged casually or after a single session. Response is usually assessed over 2 treatment cycles, and NICE advises stopping if there is less than a 30% reduction in headache days after those 2 cycles. The recommended re-treatment interval is 12 weeks. 

​

Read more: Botulinum Toxin for Chronic Migraine — who it is for, how it works, and what to expect.

Yes, it can.

Although botulinum toxin type A is also used as a preventive treatment for some adults with chronic migraine, headache can still occur as a short-term effect after aesthetic treatment.

 

When it happens, it is usually temporary and tends to settle within the first few days.

Official prescribing information describes these reactions as generally transient and occurring in the days after injection. 

​

In my clinical experience, this is seen more often in patients having treatment for the first time than in those who are already used to it.

 

That is not an absolute rule, but it is a pattern I discuss during consultation, particularly in patients who are prone to headaches.

 

A recent 2026 study reported post-treatment headache significantly more often in first-time recipients than in previously treated patients, which is consistent with that observation. 

A mild headache after treatment does not usually mean anything has gone wrong. More often, it reflects the injection process itself or the way the treated area is settling over the first few days.

Sometimes — but only in the right anatomy, and usually only to a limited degree.

​

Careful treatment can create a subtle eyebrow lift in selected patients, which may make the upper eye area look slightly more open or less heavy.

 

JCCP patient guidance explicitly notes that careful targeting can be used to achieve gentle lifting, most commonly of the eyebrows. 

 

What it cannot do is remove true excess upper-eyelid skin. If the “hooding” is mainly caused by redundant skin, fat, or a heavier structural eyelid, injectable treatment will not correct that fully. In those cases, the more appropriate intervention may be upper blepharoplasty, which is surgery to remove excess eyelid skin. 

​

This is why assessment matters. The real question is not whether the area can be treated, but why it looks hooded in the first place. In some patients, a carefully judged brow lift can help. In others, it will do very little.

And in the wrong hands, poor placement can make the eye area look heavier rather than more open, because eyelid ptosis is a recognised risk of treatment around the upper face. 

​

My approach

I assess the brow position, eyelid skin, muscle pattern, and the balance between the forehead and frown complex before deciding whether treatment is likely to help at all. If I think the result will be minimal, or that the anatomy points more towards surgery than injectable treatment, I will say so clearly.